• Novavax earned a $125 million milestone on Oct. 29, 2026, as Sanofi began a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
• The trial evaluates Nuvaxovid combined with Sanofi’s Efluelda/Fluzone High-Dose flu vaccine in adults aged 60 and older.
• A further $75 million milestone is payable upon successful completion of manufacturing technology transfer, anticipated in mid-2027.
• An additional $225 million milestone depends on a U.S. combination vaccine launch following successful completion of clinical and regulatory requirements.
• The partnership also provides royalties on Sanofi’s Nuvaxovid sales, combination products using Nuvaxovid, and new vaccines using Matrix-M.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH84613) on October 29, 2026, and is solely responsible for the information contained therein.